Business news for the stock market
Medigene AG: Medigene to present at the 6th Annual CAR-TCR Summit Europe in London
Planegg/Martinsried (pta025/15.02.2023/15:00 UTC+1)
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 6th Annual CAR-TCR Summit Europe in London from February 21 to 23, 2023.
CAR-TCR Summit Europe
Date: February 23, 2023
Presenter: Prof. Dr. Dolores Schendel, CSO
Presentation: Implementing Automation & Innovation to Improve Manufacturing of TCR-T Cells
--- end of press release ---
About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
(end)
| Emitter: |
Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany |
|
|---|---|---|
| Contact Person: | Medigene PR/IR | |
| Phone: | +49 89 2000 3333 01 | |
| E-Mail: | investor@medigene.com | |
| Website: | www.medigene.com | |
| ISIN(s): | DE000A1X3W00 (Share) | |
| Stock Exchange(s): | Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate |